Parametric Portfolio Associates’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Parametric Portfolio Associates’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-15,579	Closed	-$23K	–	4072
2016 Q1	$23K	Sell	15,579 -2,814	-15%	-$5.55K	﹤0.01%	3955
2015 Q4	$59K	Buy	+18,393	New	+$88.4K	﹤0.01%	3904
2015 Q3	–	Sell	-17,755	Closed	-$176K	–	3626
2015 Q2	$176K	Buy	+17,755	New	+$155K	﹤0.01%	3797

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parametric Portfolio Associates's NWBO Position: Q2 2016 in Review

Parametric Portfolio Associates sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 15,579 shares — an estimated $23K sold.

Parametric Portfolio Associates first reported a position in NWBO in Q2 2015 and held it in 3 quarters. The position peaked at $176K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

Parametric Portfolio Associates reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
Parametric Portfolio Associates sold 15,579 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $23K.
Parametric Portfolio Associates first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2015 and held it in 3 quarters.
Parametric Portfolio Associates's Northwest Biotherapeutics, Inc. Common stock position peaked at $176K in Q2 2015.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on Parametric Portfolio Associates's 13F filing for Q2 2016, filed 12 Aug 2016.